Literature DB >> 30196822

CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.

Adel Mohammadzadeh1, Isa Abdi Rad2, Babak Ahmadi-Salmasi3.   

Abstract

Multiple sclerosis (MS), is an autoimmune disorder of central nervous system (CNS) characterized by inflammation and demyelination. Self-tolerance impairment is considered to be induced by a combination of inherited susceptibility and environmental agents. In this work, we demonstrate that a reduction in the comparative expression of well-known inhibitory receptors (i.e., CTLA-4, PD-1, and TIM-3) is importantly linked with MS patients compared to healthy controls. The relative expression of interested genes was performed on peripheral blood mononuclear cells (PBMCs), by using quantitative real time-PCR (qRT-PCR). Our data highlighted the role of inhibitory receptors in the maintenance of immune homeostasis in autoimmune disease.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CTLA-4; Multiple sclerosis; PD-1; TIM-3

Mesh:

Substances:

Year:  2018        PMID: 30196822     DOI: 10.1016/j.jneuroim.2018.08.004

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Negative regulation of glial Tim-3 inhibits the secretion of inflammatory factors and modulates microglia to antiinflammatory phenotype after experimental intracerebral hemorrhage in rats.

Authors:  Zhou-Qing Chen; Hao Yu; Hai-Ying Li; Hai-Tao Shen; Xiang Li; Ju-Yi Zhang; Zhu-Wei Zhang; Zhong Wang; Gang Chen
Journal:  CNS Neurosci Ther       Date:  2019-01-24       Impact factor: 5.243

Review 2.  Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions.

Authors:  Yan Mi; Jinming Han; Jie Zhu; Tao Jin
Journal:  Mol Neurobiol       Date:  2021-09-03       Impact factor: 5.590

3.  Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II.

Authors:  Lili Tang; Ge Li; Yang Zheng; Chunmei Hou; Yang Gao; Ying Hao; Zhenfang Gao; Rongliang Mo; Yuxiang Li; Beifen Shen; Renxi Wang; Zhiding Wang; Gencheng Han
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 4.  The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis.

Authors:  Maria Sofia Basile; Placido Bramanti; Emanuela Mazzon
Journal:  Genes (Basel)       Date:  2022-07-24       Impact factor: 4.141

Review 5.  PD-1/PD-L Axis in Neuroinflammation: New Insights.

Authors:  Susanna Manenti; Mario Orrico; Stefano Masciocchi; Alessandra Mandelli; Annamaria Finardi; Roberto Furlan
Journal:  Front Neurol       Date:  2022-06-09       Impact factor: 4.086

Review 6.  Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.

Authors:  Ruoyu Li; Hui Li; Xiaoyan Yang; Huiru Hu; Peidong Liu; Hongbo Liu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

7.  CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.

Authors:  Stefania Kaninia; Alexandros Grammatikos; Kathryn Urankar; Shelley A Renowden; Nikunj K Patel; Mark M Gompels; Claire M Rice
Journal:  Mult Scler       Date:  2021-06-07       Impact factor: 6.312

8.  A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms.

Authors:  Alexandros Grammatikos; Sarah Johnston; Claire M Rice; Mark Gompels
Journal:  J Clin Immunol       Date:  2021-05-06       Impact factor: 8.317

9.  Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS.

Authors:  Maja Machcińska; Magdalena Kierasińska; Martyna Michniowska; Marta Maruszewska-Cheruiyot; Ludmiła Szewczak; Rafał Rola; Anna Karlińska; Michael Stear; Katarzyna Donskow-Łysoniewska
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.